Jin-Haeng Chung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5519408/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serial ultrastructural evaluation of myocardial ischemic injury after infusion of del Nido cardioplegia in the human heart. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 528-535.e2.	0.8	11
2	The differential prognostic impact of spread through air spaces in early-stage lung adenocarcinoma after lobectomy according to the pT descriptor. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 277-284.e1.	0.8	9
3	Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancer Research and Treatment, 2022, 54, 424-433.	3.0	11
4	Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 1916-1928.	1.6	94
5	Poor Prognosis of Grade 2 Spread Through Air Spaces in Neuroendocrine Tumors. Journal of Chest Surgery, 2022, 55, 101-107.	0.5	2
6	Expression-based species deconvolution and realignment removes misalignment error in multispecies single-cell data. BMC Bioinformatics, 2022, 23, 157.	2.6	0
7	Impact of Preoperative Diagnostic Biopsy Procedure on Spread Through Airspaces and Related Outcomes in Resected Stage I Non-Small Cell Lung Cancer. Chest, 2022, 162, 1199-1212.	0.8	4
8	Artificial intelligence–powered programmed death ligandÂ1 analyser reduces interobserver variation in tumour proportion score for non–small cell lung cancer with better prediction of immunotherapy response. European Journal of Cancer, 2022, 170, 17-26.	2.8	21
9	The inflamed immune phenotype (IIP): A clinically actionable artificial intelligence (AI)-based biomarker predictive of immune checkpoint inhibitor (ICI) outcomes across >16 primary tumor types Journal of Clinical Oncology, 2022, 40, 2621-2621.	1.6	1
10	Predictive Factors for Lymph Node Metastasis in Clinical Stage I Part-Solid Lung Adenocarcinoma. Annals of Thoracic Surgery, 2021, 111, 456-462.	1.3	11
11	Prognostic significance of tumor spread through air spaces in patients with stage IA part-solid lung adenocarcinoma after sublobar resection. Lung Cancer, 2021, 152, 21-26.	2.0	22
12	Tumor spread through air spaces (STAS): prognostic significance of grading in non-small cell lung cancer. Modern Pathology, 2021, 34, 549-561.	5.5	44
13	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	1.1	13
14	Lung cancer probability and clinical outcomes of baseline and new subsolid nodules detected on low-dose CT screening. Thorax, 2021, 76, 980-988.	5.6	20
15	Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2021, 39, 9026-9026.	1.6	2
16	Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types Journal of Clinical Oncology, 2021, 39, 2607-2607.	1.6	3
17	Simultaneous Pretreatment of Aspirin and Omega-3 Fatty Acid Attenuates Nuclear Factor-ήB Activation in a Murine Model with Ventilator-Induced Lung Injury. Nutrients, 2021, 13, 2258.	4.1	5
18	Prognostic Significance of the Extranodal Extension of Regional Lymph Nodes in Stage III-N2 Non-Small-Cell Lung Cancer after Curative Resection. Journal of Clinical Medicine, 2021, 10, 3324.	2.4	4

#	Article	IF	CITATIONS
19	Application of N Descriptors Proposed by the International Association for the Study of Lung Cancer in Clinical Staging. Radiology, 2021, 300, 450-457.	7.3	7
20	Tumor <scp>LAG</scp> â€3 and <scp>NYâ€ESO</scp> â€1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 619-630.	1.9	8
21	Gene Expression Profiles of Multiple Synchronous Lesions in Lung Adenocarcinoma. Cells, 2021, 10, 3484.	4.1	2
22	"Interchangeability―of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 2020, 33, 4-17.	5.5	135
23	Association of Plasma Marker of Oxidized Lipid with Histologic Plaque Instability in Patients with Peripheral Artery Disease. Annals of Vascular Surgery, 2020, 66, 554-565.	0.9	2
24	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	1.1	203
25	Stepwise Disease Progression Model of Subsolid Lung Adenocarcinoma with Cystic Airspaces. Annals of Surgical Oncology, 2020, 27, 4394-4403.	1.5	8
26	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	1.1	182
27	Estrogen receptor \hat{I}_{\pm} as a predictive biomarker for survival in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Journal of Translational Medicine, 2020, 18, 240.	4.4	12
28	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	1.1	234
29	Genetic Alterations in Preinvasive Lung Synchronous Lesions. Cancer Research and Treatment, 2020, 52, 1120-1134.	3.0	1
30	Antineutrophil Cytoplasmic Antibodies Negative Microscopic Polyangiitis With Initial Pulmonary Manifestation. Journal of Rheumatic Diseases, 2020, 27, 203-208.	1.1	0
31	Epidermal Growth Factor Receptor Gene Amplification Predicts Worse Outcome in Patients With Surgically Resected Nonadenocarcinoma Lung Cancer. Clinical Lung Cancer, 2019, 20, 7-12.e1.	2.6	5
32	Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation. BMC Pulmonary Medicine, 2019, 19, 177.	2.0	12
33	Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis. Scientific Reports, 2019, 9, 12561.	3.3	32
34	Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. Histopathology, 2019, 75, 649-659.	2.9	25
35	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	1.1	212
36	Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients. Modern Pathology, 2019, 32, 367-375.	5.5	31

#	Article	IF	CITATIONS
37	PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future. Journal of Pathology and Translational Medicine, 2019, 53, 199-206.	1.1	51
38	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. Cancer Research and Treatment, 2019, 51, 1086-1097.	3.0	59
39	Clinical Significance of Pleural Attachment and Indentation of Subsolid Nodule Lung Cancer. Cancer Research and Treatment, 2019, 51, 1540-1548.	3.0	26
40	Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung. Journal of Pathology and Translational Medicine, 2019, 53, 86-93.	1.1	3
41	Prognostic Impact of DNA Repair Protein Expression in Non-Small Cell Lung Cancers Treated with Platinum-Based Chemotherapy and Subsequent Curative Lung Resection. Oncology, 2018, 95, 20-30.	1.9	3
42	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. Journal of Thoracic Oncology, 2018, 13, 205-217.	1.1	33
43	Pathological prognostic factors of recurrence in early stage lung adenocarcinoma. ANZ Journal of Surgery, 2018, 88, 327-331.	0.7	15
44	Effect of computed tomography window settings and reconstruction plane on 8th edition T-stage classification in patients with lung adenocarcinoma manifesting as a subsolid nodule. European Journal of Radiology, 2018, 98, 130-135.	2.6	23
45	Targeted Sequencing Analysis of Pulmonary Adenocarcinoma with Multiple Synchronous Ground-Glass/Lepidic Nodules. Journal of Thoracic Oncology, 2018, 13, 1776-1783.	1.1	22
46	Potential Oncogenic Role and Prognostic Implication of MicroRNA-155-5p in Oral Squamous Cell Carcinoma. Anticancer Research, 2018, 38, 5193-5200.	1.1	31
47	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. PLoS ONE, 2018, 13, e0198634.	2.5	25
48	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. Yonsei Medical Journal, 2018, 59, 202.	2.2	7
49	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of Thoracic Oncology, 2018, 13, 1302-1311.	1.1	589
50	Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance. Journal of Pathology and Translational Medicine, 2018, 52, 130-132.	1.1	1
51	A Clinicopathologic Study of 220 Cases of Pulmonary Sclerosing Pneumocytoma in Korea: A Nationwide Survey. Journal of Pathology and Translational Medicine, 2018, , .	1.1	0
52	Increased expression of interferon-λ in minor salivary glands of patients with primary Sjögren's syndrome and its synergic effect with interferon-α on salivary gland epithelial cells. Clinical and Experimental Rheumatology, 2018, 36 Suppl 112, 31-40.	0.8	6
53	Comparison of Prognosis of Solid and Part-Solid Node-Negative Adenocarcinoma With the Same Invasive Component Size. Annals of Thoracic Surgery, 2017, 103, 1654-1660.	1.3	6
54	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. Journal of Thoracic Oncology, 2017, 12, 334-346.	1.1	113

#	Article	IF	CITATIONS
55	Synchrotron tomographic images from human lung adenocarcinoma: Threeâ€dimensional reconstruction and histologic correlations. Microscopy Research and Technique, 2017, 80, 1141-1148.	2.2	5
56	Reply: YAP is a Key Factor to Improve the Management of Cancer Treatments. Annals of Surgical Oncology, 2017, 24, 644-645.	1.5	1
57	PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. Oncotarget, 2017, 8, 98524-98532.	1.8	40
58	Molecular Testing of Lung Cancers. Journal of Pathology and Translational Medicine, 2017, 51, 242-254.	1.1	26
59	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement. Journal of Clinical Oncology, 2017, 35, 2613-2618.	1.6	260
60	MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status. Oncotarget, 2017, 8, 8484-8498.	1.8	44
61	Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma. Oncotarget, 2017, 8, 66178-66194.	1.8	50
62	Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors. Cancer Research and Treatment, 2017, 49, 104-115.	3.0	21
63	EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy. OncoTargets and Therapy, 2016, Volume 9, 5153-5162.	2.0	11
64	Expression of Na ⁺ –K ⁺ -2Cl ^{â^'} cotransporter isoform 1 (NKCC1) predicts poor prognosis in lung adenocarcinoma and <i>EGFR</i> -mutated adenocarcinoma patients. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 237-244.	0.5	22
65	Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes. European Radiology, 2016, 26, 3660-3668.	4.5	49
66	Radiologic Characteristics of Surgically Resected Non-Small Cell Lung Cancer With ALK Rearrangement or EGFR Mutations. Annals of Thoracic Surgery, 2016, 101, 473-480.	1.3	50
67	Prognostic value of wingless-type proteins in non-small cell lung cancer patients: a meta-analysis. Translational Lung Cancer Research, 2016, 5, 436-442.	2.8	15
68	Aquaporin 1 Is an Independent Marker of Poor Prognosis in Lung Adenocarcinoma. Journal of Pathology and Translational Medicine, 2016, 50, 251-257.	1.1	19
69	ROS1 gene rearrangement and copy number gain in non-small cell lung cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 45-52.	2.8	19
70	Immunohistochemical demonstration of alteration of β-catenin during tumor metastasis by different mechanisms according to histology in lung cancer. Experimental and Therapeutic Medicine, 2015, 9, 311-318.	1.8	6
71	Recurrence Risk-Scoring Model for Stage I Adenocarcinoma of the Lung. Annals of Surgical Oncology, 2015, 22, 4089-4097.	1.5	22
72	Frequent aerogenous spread with decreased E-cadherin expression of ROS1- rearranged lung cancer predicts poor disease-free survival. Lung Cancer, 2015, 89, 343-349.	2.0	39

#	Article	IF	CITATIONS
73	A Rare Case of Primary Tubular Adenocarcinoma of the Thymus, Enteric Immunophenotype: A Case Study and Review of the Literature. Journal of Pathology and Translational Medicine, 2015, 49, 331-334.	1.1	11
74	Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (<i>EGFR</i>)-Mutant Lung Adenocarcinoma. Journal of Pathology and Translational Medicine, 2015, 49, 382-388.	1.1	19
75	Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. Translational Lung Cancer Research, 2015, 4, 149-55.	2.8	21
76	Heterotopic Pancreas in Omphalomesenteric Duct Remnant Results in Persistent Umbilical Discharge. Korean Journal of Pathology, 2014, 48, 323.	1.3	18
77	FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 547-558.	2.8	58
78	Guideline Recommendations for Testing of <i>ALK</i> Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group. Korean Journal of Pathology, 2014, 48, 1.	1.3	22
79	Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry. Lung Cancer, 2014, 83, 316-323.	2.0	40
80	MET Gene Copy Number Gain is an Independent Poor Prognostic Marker in Korean Stage I Lung Adenocarcinomas. Annals of Surgical Oncology, 2014, 21, 621-628.	1.5	17
81	Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer. Lung Cancer, 2014, 86, 262-267.	2.0	13
82	Cytoplasmic YAP Expression is Associated with Prolonged Survival in Patients with Lung Adenocarcinomas and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment. Annals of Surgical Oncology, 2014, 21, 610-618.	1.5	15
83	Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respiratory Medicine, 2014, 108, 388-394.	2.9	39
84	In Reply: IgG4 Related Disease and Sensorineural Hearing Loss. Clinical and Experimental Otorhinolaryngology, 2014, 7, 238.	2.1	2
85	Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 427-436.	2.8	24
86	ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 597-599.	2.8	12
87	High Expression of Sonic Hedgehog Signaling Proteins Is Related to the Favorable Outcome, EGFR Mutation, and Lepidic Predominant Subtype in Primary Lung Adenocarcinoma. Annals of Surgical Oncology, 2013, 20, 570-576.	1.5	13
88	Alteration of the E-cadherin/β-Catenin Complex Predicts Poor Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment. Annals of Surgical Oncology, 2013, 20, 545-552.	1.5	16
89	Guideline Recommendations for <i>EGFR</i> Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group. Korean Journal of Pathology, 2013, 47, 100.	1.3	14
90	Alteration of the E-Cadherin/Î ² -Catenin Complex Is an Independent Poor Prognostic Factor in Lung Adenocarcinoma. Korean Journal of Pathology, 2013, 47, 44.	1.3	41

#	Article	IF	CITATIONS
91	Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of <i>EGFR </i> Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment. Korean Journal of Pathology, 2013, 47, 52.	1.3	31
92	High concordance of <i>EGFR</i> mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. Cancer Cytopathology, 2013, 121, 311-319.	2.4	51
93	A Comprehensive Comparative Analysis of the Histomorphological Features of ALK-Rearranged Lung Adenocarcinoma Based on Driver Oncogene Mutations: Frequent Expression of Epithelial-Mesenchymal Transition Markers than Other Genotype. PLoS ONE, 2013, 8, e76999.	2.5	58
94	High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features. Journal of Thoracic Oncology, 2012, 7, 323-330.	1.1	143
95	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer. Lung Cancer, 2012, 76, 403-409.	2.0	149
96	Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 601-609.	2.8	25
97	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer, 2011, 73, 176-182.	2.0	152
98	Epithelioid Hemangioendothelioma of the Femur with Benign Cystic Appearance. Journal of the Korean Society of Radiology, 2011, 65, 607.	0.2	0
99	Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization with Correlation of ALK Protein Expression. Journal of Thoracic Oncology, 2011, 6, 1359-1366.	1.1	151
100	Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non-small Cell Lung Cancer After Surgery. Journal of Thoracic Oncology, 2011, 6, 716-724.	1.1	89
101	Propylthiouracil-Induced Nonspecific Interstitial Pneumonia. Chest, 2011, 139, 687-690.	0.8	14
102	DNA methylation profile during multistage progression of pulmonary adenocarcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 201-211.	2.8	49
103	Screening of Anaplastic Lymphoma Kinase Rearrangement by Immunohistochemistry in Non-small Cell Lung Cancer: Correlation with Fluorescence In Situ Hybridization. Journal of Thoracic Oncology, 2011, 6, 466-472.	1.1	266
104	Loss of PTEN Expression is an Independent Poor Prognostic Factor in Non-small Cell Lung Cancer. Korean Journal of Pathology, 2011, 45, 329.	1.3	9
105	The Accuracy of Frozen Section Diagnosis of Pulmonary Nodules: Evaluation of Inflation Method during Intraoperative Pathology Consultation with Cryosection. Journal of Thoracic Oncology, 2010, 5, 39-44.	1.1	48
106	Epidermal Growth Factor Receptor Mutation and p53 Overexpression during the Multistage Progression of Small Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2010, 5, 964-969.	1.1	34
107	Bone Scintigraphy Findings of A Case with Maffucci's Syndrome. Nuclear Medicine and Molecular Imaging, 2010, 44, 150-153.	1.0	3
108	Reliability of chromogenic in situ hybridization for epidermal growth factor receptor gene copy number detection in non-small-cell lung carcinomas: A comparison with fluorescence in situ hybridization study. Lung Cancer, 2010, 67, 301-305.	2.0	23

#	Article	IF	CITATIONS
109	Pulmonary Nodular Lymphoid Hyperplasia. Tuberculosis and Respiratory Diseases, 2010, 69, 212.	1.8	0
110	Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules with Ground-Glass Opacity Differentiates Multicentric Origin from Intrapulmonary Spread. Journal of Thoracic Oncology, 2009, 4, 1490-1495.	1.1	103
111	Differential Expression of Glut1 in Pulmonary Neuroendocrine Tumors: Correlation with Histological Grade. Korean Journal of Pathology, 2009, 43, 201.	1.3	2
112	MR Imaging Features of a Solitary Subcutaneous Metastasis from a Gastric Adenocarcinoma: A Case Report. Journal of the Korean Society of Radiology, 2009, 60, 159.	0.2	0
113	A simple inflation method for frozen section diagnosis of minute precancerous lesions of the lung. Lung Cancer, 2008, 59, 198-202.	2.0	28
114	Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer, 2008, 61, 54-60.	2.0	48
115	High correlations between primary tumours and loco-regional metastatic lymph nodes in non-small-cell lung cancer with respect to glucose transporter type 1-mediated 2-deoxy-2-F18-fluoro-d-glucose uptake. European Journal of Cancer, 2008, 44, 692-698.	2.8	29
116	Primary Mediastinal Synovial Sarcoma. Journal of Lung Cancer, 2008, 7, 29.	0.2	2
117	Consideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PET. Journal of Surgical Oncology, 2006, 94, 607-613.	1.7	12
118	Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. Journal of Nuclear Medicine, 2004, 45, 999-1003.	5.0	55
119	Prognostic significance of stem cell-related marker expression and its correlation with histologic subtypes in lung adenocarcinoma. Oncotarget, 0, 7, 42502-42512.	1.8	46